Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma
Fiche du document
Date
2013
Discipline
Type de document
Périmètre
Langue
Identifiants
- handle: 10670/1.c1kntb
- halshs: halshs-00752571
- doi: 10.1007/s40258-013-0011-7
Relations
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s40258-013-0011-7
Collection
Organisation
Mots-clés
Cost-effectiveness Pegfilgrastim Filgrastim I - Health, Education, and Welfare/I.I1 - Health I - Health, Education, and Welfare/I.I1 - Health/I.I1.I11 - Analysis of Health Care Markets I - Health, Education, and Welfare/I.I1 - Health/I.I1.I18 - Government Policy • Regulation • Public HealthSujets proches
Wellness Personal health Biography--HealthCiter ce document
Lionel Perrier et al., « Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma », HAL-SHS : économie et finance, ID : 10.1007/s40258-013-0011-7
Métriques
Partage / Export
Résumé
International audience